Weekly View

ICER Weekly View: March 15, 2019

From the desk of David Whitrap What a week. We experienced a massive bribery scandal that helped students gain admission to elite universities, the international grounding of an entire fleet of aircraft, and the near inevitability of President Trump’s first veto. At least we had Pi Day mixed in to help lighten the mood. But this […]

Read More

ICER Weekly View: March 8, 2019

From the desk of David Whitrap Hello everyone. For all of you who attended or viewed yesterday’s public ICER meeting on the treatments for spinal muscular atrophy, I hope you’ll agree that the dialogue throughout the day demonstrated the critical role patients play during each of ICER’s assessments. We warmly thank each of the patient […]

Read More

ICER Weekly View: March 1, 2019

From the desk of David Whitrap Hello everyone. This week, a self-proclaimed “fixer” testified in front of the House Oversight Committee. And the day before that, the Senate Finance Committee held a separate hearing to identify some fixes of its own for our country’s drug pricing dysfunction. Time will tell which of these sessions will […]

Read More

ICER Weekly View: February 22, 2019

From the desk of David Whitrap Hello, everyone. It’s a busy day here at ICER. In addition to releasing our revised Evidence Report on treatments for spinal muscular atrophy later this afternoon, we will also announce the topic for our next drug assessment. Stay tuned… But this morning, let’s take a look at: ICER in […]

Read More

ICER Weekly View: February 15, 2019

From the desk of David Whitrap Good morning, everyone. If you’re feeling overwhelmed by this week’s important questions (e.g., Is it really possible that Americans spend more than $18 billion per year on Valentine’s Day gifts? And why exactly are there so many mattresses going on sale this weekend?), I hope you can find comfort […]

Read More

ICER Weekly View: February 8, 2019

From the desk of David Whitrap Good morning, everyone. Below, I’ll touch on what Tuesday’s State of the Union address might mean for the health care industry. But before we get there, I’d first like to state my appreciation for members of both political parties breaking into an impromptu chorus of “Happy Birthday” for Judah Samet, […]

Read More

ICER Weekly View: February 1, 2019

From the desk of David Whitrap Good morning, everyone. I’m sure many of you are gearing up for an exciting Super Bowl, but I personally will have difficulty rooting for either 1) the team that stole a championship from my hometown or 2) the team that abandoned my hometown altogether. So instead, I plan on […]

Read More

ICER Weekly View: January 25, 2019

From the desk of David Whitrap In the national conversation around drug pricing, there remains a stark divide between 1) those who believe that the current market dynamics are unsustainable, and 2) those who stand to profit by preserving the status quo. I recently learned that “status quo” is actually an abbreviated form of the original Latin […]

Read More

ICER Weekly View: January 18, 2019

From the desk of David Whitrap Good morning everyone. Here in Boston, we’ve seen exactly 0.2 inches of snowfall this winter. For those keeping score at home, that’s 22.7 inches less than what we’d seen by this time last year, and it’s half of what’s already fallen this season in famously frigid cities like El […]

Read More

ICER Weekly View: January 11, 2019

From the desk of David Whitrap Good morning, everyone. This week’s JP Morgan Healthcare Conference brought us some big M&A deals, promising clinical trial data, and a slight (okay, very slight) improvement toward gender balance among the executives who presented. Let’s take a brief look at the news… Pharmaceutical News On the heels of Bristol-Myers […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP